Moxifloxacin
- TRADE NAMES: Avelox (Bayer); Moxeza (Alcon)
- INDICATIONS: Various infections caused by susceptible organisms
- CLASS: Antibiotic, Antibiotic; fluoroquinolone, Antimicrobial, Drug-resistant antituberculosis agent
- HALF-LIFE: 12 hours
Alfuzosin, Aminophylline, Amiodarone, Amitriptyline, Antacids, Arsenic, Artemether/Lumefantrine, Asenapine, Atomoxetine, BCG Vaccine, Benperidol, Bepridil, Bretylium, Chloroquine, Ciprofloxacin, Corticosteroids, Cyclosporine, Degarelix, Didanosine, Disopyramide, Dronedarone, Droperidol, Erythromycin, Gadobutrol, Haloperidol, Hydroxychloroquine, Insulin, Lanthanum, Levomepromazine, Magnesium salts, Mefloquine, Mizolastine, Mycophenolate, Nilotinib, NSAIDs, Oral iron, Oral typhoid vaccine, Pentamidine, Phenothiazines, Pimavanserin, Pimozide, Probenecid, Procainamide, QT prolonging agents, Quinapril, Quinidine, Quinine, Ribociclib, Sevelamer, Sotalol, Strontium Ranelate, Sucralfate, Sulfonylureas, Tetrabenazine, Thioridazine, Tricyclic antidepressants, Vandetanib, Vitamin K antagonists, Warfarin, Zinc, Ziprasidone, Zolmitriptan, Zuclopenthixol
PREGNANCY CATEGORY: C
Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis.
Moxeza is for topical ophthalmic use only.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
